After 6 years with Xolair; a 3-year withdrawal follow-up
Nopp, A. ; Johansson, S. G. O. ; Adedoyin, J. ; Ankerst, Jaro LU
; Palmqvist, M.
and Oman, H.
(2010)
In Allergy
65(1).
p.56-60
- Abstract
- P>Background: This study reports the clinical and immunological state of patients 3 years after a 6-year period of Xolair treatment for severe allergic asthma. Methods: The patient's cat allergen sensitivity, measured as CD-sens, IgE and IgE- and IgG4 antibodies, was analysed and compared with asthma severity evaluated from FEV1 and a questionnaire. Results: Three years after treatment with Xolair was stopped, 12/18 patients reported improved or unchanged asthma compared with ongoing Xolair treatment. Most of the patients were in a stable clinical condition, 16/18 had not increased nightly asthma attacks and 14/18 little or no increase in medication. The CD-sens to cat was still significantly lower (P < 0.02) than untreated patients... (More)
- P>Background: This study reports the clinical and immunological state of patients 3 years after a 6-year period of Xolair treatment for severe allergic asthma. Methods: The patient's cat allergen sensitivity, measured as CD-sens, IgE and IgE- and IgG4 antibodies, was analysed and compared with asthma severity evaluated from FEV1 and a questionnaire. Results: Three years after treatment with Xolair was stopped, 12/18 patients reported improved or unchanged asthma compared with ongoing Xolair treatment. Most of the patients were in a stable clinical condition, 16/18 had not increased nightly asthma attacks and 14/18 little or no increase in medication. The CD-sens to cat was still significantly lower (P < 0.02) than untreated patients with allergic asthma and lower than expected from their serum IgE antibody levels. Conclusion: Most of the patients in this study had, still 3 years after closing of 6 years Xolair treatment, a surprisingly mild and stable asthma. Interestingly, the observed, considerable, downregulation of basophil allergen sensitivity, CD-sens, most likely representing mast cell allergen sensitivity, contributed to the clinical results. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1535590
- author
- Nopp, A.
; Johansson, S. G. O.
; Adedoyin, J.
; Ankerst, Jaro
LU
; Palmqvist, M.
and Oman, H.
- organization
- publishing date
- 2010
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- omalizumab, CD-sens, IgE antibody
- in
- Allergy
- volume
- 65
- issue
- 1
- pages
- 56 - 60
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000272630200008
- scopus:72049131312
- pmid:19796193
- ISSN
- 1398-9995
- DOI
- 10.1111/j.1398-9995.2009.02144.x
- language
- English
- LU publication?
- yes
- id
- 21d15b7f-66e9-4a76-a1df-283fd62b27ac (old id 1535590)
- date added to LUP
- 2016-04-01 14:00:53
- date last changed
- 2024-11-07 14:06:21
@article{21d15b7f-66e9-4a76-a1df-283fd62b27ac,
abstract = {{P>Background: This study reports the clinical and immunological state of patients 3 years after a 6-year period of Xolair treatment for severe allergic asthma. Methods: The patient's cat allergen sensitivity, measured as CD-sens, IgE and IgE- and IgG4 antibodies, was analysed and compared with asthma severity evaluated from FEV1 and a questionnaire. Results: Three years after treatment with Xolair was stopped, 12/18 patients reported improved or unchanged asthma compared with ongoing Xolair treatment. Most of the patients were in a stable clinical condition, 16/18 had not increased nightly asthma attacks and 14/18 little or no increase in medication. The CD-sens to cat was still significantly lower (P < 0.02) than untreated patients with allergic asthma and lower than expected from their serum IgE antibody levels. Conclusion: Most of the patients in this study had, still 3 years after closing of 6 years Xolair treatment, a surprisingly mild and stable asthma. Interestingly, the observed, considerable, downregulation of basophil allergen sensitivity, CD-sens, most likely representing mast cell allergen sensitivity, contributed to the clinical results.}},
author = {{Nopp, A. and Johansson, S. G. O. and Adedoyin, J. and Ankerst, Jaro and Palmqvist, M. and Oman, H.}},
issn = {{1398-9995}},
keywords = {{omalizumab; CD-sens; IgE antibody}},
language = {{eng}},
number = {{1}},
pages = {{56--60}},
publisher = {{Wiley-Blackwell}},
series = {{Allergy}},
title = {{After 6 years with Xolair; a 3-year withdrawal follow-up}},
url = {{http://dx.doi.org/10.1111/j.1398-9995.2009.02144.x}},
doi = {{10.1111/j.1398-9995.2009.02144.x}},
volume = {{65}},
year = {{2010}},
}